FVIII clearance in mice that lack LRP, LDLR, or both. At 4 weeks after the final pI:pC injection, purified human FVIII (20 IU) was intravenously administered into (A) control mice (▵) (n = 5) and LDLR–/– mice (▴) (n = 5) and into (B) LRP– mice (○) (n = 5) and LDLR–/– LRP– mice (•) (n = 5). Human FVIII removal from plasma was monitored at indicated time points. (C) LDLR–/–LRP– mice were intravenously injected with 2 × 109 plaque-forming units Ad-CMV-β-Gal (▪) (n = 8) or Ad-CMV-LDLR (□) (n = 8). Five days after adenovirus injection, animals were intravenously injected with purified human FVIII (20 IU), and its plasma removal was monitored at indicated time points. *P < .01, significantly different from that of control Ad-CMV-β-Gal–treated mice; Mann-Whitney U test. Data represent geometric mean values and 68% confidence intervals.
